Why the study?
Does apixaban remain the drug of choice for patients with atrial fibrillation and diabetes?
Does apixaban remain the drug of choice for patients with atrial fibrillation and diabetes?
Answers are grounded in this paper and cite their sources.
This article discusses the role of apixaban and other NOACs compared to VKAs for stroke prevention in patients with atrial fibrillation and diabetes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hai et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: